# US 2023/0065820 A1 · Telehealth and microdosing platform for psychedelic-assisted therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065820 A1
- Document ID: US20230065820A1
- Status: Published application
- Kind: A1
- Application number: 17/459,998
- Filed: 2021-08-27
- Published: 2023-03-02
- Earliest claimed: 2021-08-27
- Assignees: Psilothera, Inc.
- Applicants: Psilothera, Inc.
- Inventors: Charles John Atanasio, JR.; John Patrick Atanasio, SR.
- Web page: https://patentgrep.com/patent/US20230065820A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/70: relating to mental therapies, e.g. psychological therapy or autogenous training
- G16H 80/00: ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

One embodiment provides a method comprising providing to a patient user a questionnaire comprising questions inquiring about well-being of the patient user, receiving responses of the patient user to the questionnaire, and generating a patient user profile by applying machine learning to the responses. The patient user profile comprises diagnostic questions customized for the patient user. The method further comprises providing the patient user profile to a third party user, and initiating a video teleconference between the patient user and the third party user during which the third party user asks the patient user the diagnostic questions to assess and diagnose a mental health of the patient user. The method further comprises providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis. The plan indicates at least one dosing session involving psychedelics for the patient user to complete.

## Claims

### Claim 1

A method comprising:
providing, on a first device associated with a patient user, a questionnaire comprising questions inquiring about well-being of the patient user;
receiving, from the first device, responses of the patient user to the questionnaire;
generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user;
providing, on a second device associated with a third party user, the patient user profile;
initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and
providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to consume during the at least one dosing session.

### Claim 2 (depends on 1)

The method of claim 1, wherein the third party user is a licensed therapist.

### Claim 3 (depends on 1)

The method of claim 1, wherein each dosing session is one of a microdosing session or a high dose session.

### Claim 4 (depends on 1)

The method of claim 1, further comprising:
requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.

### Claim 5 (depends on 4)

The method of claim 4, further comprising:
requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.

### Claim 6 (depends on 5)

The method of claim 5, further comprising:
monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses.

### Claim 7 (depends on 6)

The method of claim 6, further comprising:
requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan.

### Claim 8

A system, comprising:
at least one processor; and
a non-transitory processor-readable memory device storing instructions that when executed by the at least one processor causes the at least one processor to perform operations including:
providing, on a first device associated with a patient user, a questionnaire comprising questions inquiring about well-being of the patient user;
receiving, from the first device, responses of the patient user to the questionnaire;
generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user;
providing, on a second device associated with a third party user, the patient user profile;
initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and
providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to consume during the at least one dosing session.

### Claim 9 (depends on 8)

The system of claim 8, wherein the third party user is a licensed therapist.

### Claim 10 (depends on 8)

The system of claim 8, wherein each dosing session is one of a microdosing session or a high dose session.

### Claim 11 (depends on 8)

The system of claim 8, wherein the operations include:
requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.

### Claim 12 (depends on 11)

The system of claim 11, wherein the operations include:
requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.

### Claim 13 (depends on 12)

The system of claim 12, wherein the operations include:
monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses.

### Claim 14 (depends on 13)

The system of claim 13, wherein the operations include:
requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan.

### Claim 15

A non-transitory processor-readable medium that includes a program that when executed by a processor performs a method comprising:
providing, on a first device associated with a patient user, a questionnaire comprising questions inquiring about well-being of the patient user;
receiving, from the first device, responses of the patient user to the questionnaire;
generating a patient user profile by applying machine learning to the responses, wherein the patient user profile comprises diagnostic questions customized for the patient user;
providing, on a second device associated with a third party user, the patient user profile;
initiating, via the first device and the second device, a video teleconference between the patient user and the third party user, wherein the third party user asks the patient user the diagnostic questions during the video teleconference to assess and diagnose a mental health of the patient user; and
providing the patient user with a therapeutic treatment plan prescribed by the third party user based on the assessment and diagnosis, wherein the therapeutic treatment plan is indicative of at least one dosing session for the patient user to complete, frequency of the at least one dosing session, and an amount of psychedelics for the patient user to consume during the at least one dosing session.

### Claim 16 (depends on 15)

The non-transitory processor-readable medium of claim 15, wherein the third party user is a licensed therapist.

### Claim 17 (depends on 15)

The non-transitory processor-readable medium of claim 15, wherein each dosing session is one of a microdosing session or a high dose session.

### Claim 18 (depends on 15)

The non-transitory processor-readable medium of claim 15, wherein the method further comprises:
requesting feedback from the patient user, wherein the feedback is indicative of an experience and effects of the patient user after a dosing session.

### Claim 19 (depends on 18)

The non-transitory processor-readable medium of claim 18, wherein the method further comprises:
requesting updated responses of the patient user to the questionnaire at pre-determined intervals after a first dosing session.

### Claim 20 (depends on 19)

The non-transitory processor-readable medium of claim 19, wherein the method further comprises:
monitoring satisfaction of the patient user with the therapeutic treatment plan based on at least one of the feedback or the updated responses;
requesting the third party user to make an adjustment to the therapeutic treatment plan based on at least one of the feedback, the updated responses, or the satisfaction of the patient user with the therapeutic treatment plan; and
uploading and storing in one or more electronic medical records of the patient user the feedback, the updated responses, one or more certifications of the third party user, and at least one record of at least one session between the patient user and the third party user.
